LENSAR, Inc.
NASDAQ:LNSRMedical - Devices
-$0.51 today
- Market cap
- $57.05M
- Beta
- 0.87
- P/E (TTM)
- 2.4
- EPS (TTM)
- $2.42
Volume 0.04M
Average 0.09M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
LENSAR, Inc.
NASDAQ:LNSR
Intrinsic Alpha fair value
Locked
Current Price
$4.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +18.2% | +17.4% (3yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +18.2% over three years. Forward estimates point to Revenue at +17.4% (3yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Anteris Technologies Global Corp. NASDAQ:AVR | $528.22M | $5.42 | Not rated | -2.3 | +50.59% |
Profound Medical Corp. NASDAQ:PROF | $271.77M | $7.42 | Not rated | -6.3 | +12.07% |
Anika Therapeutics, Inc. NASDAQ:ANIK | $179.50M | $13.40 | Overvalued | -17.3 | +42.80% |
TriSalus Life Sciences, Inc. NASDAQ:TLSI | $149.93M | $2.43 | Not rated | -7.4 | -56.15% |
MaxCyte, Inc. NASDAQ:MXCT | $122.82M | $1.19 | Not rated | -3.2 | -21.47% |
Owlet, Inc. NYSE:OWLT | $100.52M | $3.44 | Not rated | -0.4 | -72.99% |
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | $69.86M | $3.39 | Not rated | -1.3 | -79.17% |
Cardiff Oncology, Inc. NASDAQ:CRDF | $56.49M | $0.73 | Not rated | -1.8 | -54.46% |
Rapid Micro Biosystems, Inc. NASDAQ:RPID | $29.72M | $0.65 | Not rated | -1.5 | -72.66% |
Continue the stock analysis
Jump to another research area for this company.